Tags

Type your tag names separated by a space and hit enter

Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Vaccine. 2010 Oct 18; 28(44):7233-40.V

Abstract

Our previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions.

Authors+Show Affiliations

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20732469

Citation

Zhao, Guangyu, et al. "Induction of Protection Against Divergent H5N1 Influenza Viruses Using a Recombinant Fusion Protein Linking Influenza M2e to Onchocerca Volvulus Activation Associated Protein-1 (ASP-1) Adjuvant." Vaccine, vol. 28, no. 44, 2010, pp. 7233-40.
Zhao G, Du L, Xiao W, et al. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine. 2010;28(44):7233-40.
Zhao, G., Du, L., Xiao, W., Sun, S., Lin, Y., Chen, M., Kou, Z., He, Y., Lustigman, S., Jiang, S., Zheng, B. J., & Zhou, Y. (2010). Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine, 28(44), 7233-40. https://doi.org/10.1016/j.vaccine.2010.08.049
Zhao G, et al. Induction of Protection Against Divergent H5N1 Influenza Viruses Using a Recombinant Fusion Protein Linking Influenza M2e to Onchocerca Volvulus Activation Associated Protein-1 (ASP-1) Adjuvant. Vaccine. 2010 Oct 18;28(44):7233-40. PubMed PMID: 20732469.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. AU - Zhao,Guangyu, AU - Du,Lanying, AU - Xiao,Wenjun, AU - Sun,Shihui, AU - Lin,Yongping, AU - Chen,Min, AU - Kou,Zhihua, AU - He,Yuxian, AU - Lustigman,Sara, AU - Jiang,Shibo, AU - Zheng,Bo-Jian, AU - Zhou,Yusen, Y1 - 2010/08/21/ PY - 2010/05/31/received PY - 2010/08/01/revised PY - 2010/08/06/accepted PY - 2010/8/25/entrez PY - 2010/8/25/pubmed PY - 2011/1/15/medline SP - 7233 EP - 40 JF - Vaccine JO - Vaccine VL - 28 IS - 44 N2 - Our previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20732469/Induction_of_protection_against_divergent_H5N1_influenza_viruses_using_a_recombinant_fusion_protein_linking_influenza_M2e_to_Onchocerca_volvulus_activation_associated_protein_1__ASP_1__adjuvant_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01194-1 DB - PRIME DP - Unbound Medicine ER -